NVAX Q3 2020 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$157M+6163.4% YoY

Gross Profit

$157M100.0% margin

Operating Income

-$194M-123.5% margin

Net Income

-$197M-125.7% margin

EPS (Diluted)

$-3.21

QoQ Revenue Growth

+341.8%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$15M

Stock-Based Comp.

$66M

Balance Sheet

Total Assets

$944M

Total Liabilities

$838M

Stockholders' Equity

$106M

Cash & Equivalents

$334M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$157M	$3M	+6163.4%
Gross Profit	$157M	$3M	+6163.4%
Operating Income	-$194M	-$15M	-1194.1%
Net Income	-$197M	-$18M	-993.6%

Revenue Segments

Grant

$114M73%

Government Contract

$43M27%